Navigation Links
Cell Therapeutics Updates Shareholders on Trading
Date:2/11/2009

e trading in Italy. The Company believes that it is currently in compliance with all undertakings for filing and reporting obligations in Italy as agreed with the Borsa Italiana and CONSOB when the shares were accepted for listing in Italy.

The Company is diligently working with the Borsa Italiana, CONSOB and the NASDAQ Stock Market to have one or both markets resume trading in the Company's common stock.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.CellTherapeutics.com.

This press release contains forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect future results. The risks and uncertainties include that the Company may not be able satisfy the Italian regulatory authorities requests for information; the Borsa Italiana may choose not to lift the trading halt in Italy; the Company's current extension of time to comply with the NASDAQ listing requirements may not be extended by the NASDAQ Qualification Panel and the Company may be delisted by NASDAQ; the Company's operating expenses continue to exceed its net revenues and the Company will continue to need to raise capital to fund its operating expenses; as well as other risks listed or described from time to time in the Company's most recent filings with the SEC on Forms 10-K, 8-K and 10-Q. Except as required by law, the Company does not intend to update any of the statements in this press release upon further developments.

     Media Contact:
     Dan Eramian
     T: 206.272.4343
     C: 206.854.1200
     E: media@ctiseattle.com
   
'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Transition Therapeutics Announces Second Quarter Fiscal 2009 Financial Results
2. Arete Therapeutics Initiates Phase IIa Clinical Trial for AR9281, a Novel s-EH Inhibitor to Treat Type 2 Diabetes
3. Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2009 Financial Results on Wednesday, February 11th, at 4:30 P.M. EST
4. Transition Therapeutics Announces Completion of Patient Enrolment of Phase 2 Study of TT-223 in Type 2 Diabetes Patients
5. Nile Therapeutics to Present at the 2009 BIO CEO & Investor Conference
6. Nile Therapeutics to Present at the 27th Annual J.P. Morgan Healthcare Conference
7. Merck Serono and Apitope Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis
8. AHRQ Announces New Web Site on Emerging Issues in Medical Therapeutics
9. Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals
10. Orexigen(R) Therapeutics to Speak at J.P. Morgan Healthcare Conference
11. Prime Therapeutics Hires Steven Blumenfield as Chief Marketing Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/20/2014)... December 20, 2014 Weddingshe.com has recently ... launched a site-wide promotion of special occasion dresses for ... popular supplier of special occasion dresses for global women. ... with big discounts, up to 80% off. Among the ... Sequins Short Sweet 16 Dress) is very popular. What’s ...
(Date:12/20/2014)... December 20, 2014 DePuy Pinnacle ... metal-on-metal version of the artificial hip system was ... and federal courts, Bernstein Liebhard LLP reports. According ... County Superior Court on December 2nd, counsel in ... deposition of plaintiffs on November 19, 2014, with ...
(Date:12/20/2014)... Recently, VogueQueen.com, a leading wedding dress wholesaler and retailer, ... for 2015. Great discounts are now offered on all ... get a discount, up to 80% off, when they ... 30, 2015. , VogueQueen.com has recently released its new ... promotion. Many customers worldwide like VogueQueen’s special designs which ...
(Date:12/20/2014)... New York, New York (PRWEB) December 20, 2014 ... ) continue to move forward in U.S. ... a new study which suggests that children treated ... prolactin, a hormone linked to breast development and ... Psychopharmacology, looked at 34 children and adolescents who ...
(Date:12/20/2014)... 2014 Recently, AngelWeddingDress.com has introduced its ... for the coming Christmas. In the promotion, all buyers ... , “We have something special for the women who ... season. Moreover, our new collections of 2015 dresses have ... now at greatly discounted prices. Visit our website now ...
Breaking Medicine News(10 mins):Health News:Tons of New-in Winter Sweet 16 Dresses from Weddingshe Online Now 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4Health News:VogueQueen Big Sale Online For The Coming 2015 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4Health News:AngelWeddingDress Has Introduced Its Special Offer For The Coming Christmas 2
... ANGELES, Oct. 3 Pink tags will be ... the supermarket chain partners,with vendors and suppliers to ... Throughout the month, pink tags can be found ... identify participating products,customers can purchase to support breast ...
... Interested in Stopping their Periods, But Unsure,About Medical Implications, ... of,women in a national survey say that they are ... aren,t sure if it,s safe. Yet when,physicians are polled, ... menstruation is, in fact, medically safe and,acceptable. The survey ...
... than the two thirds of the women in a ... their menstrual periods but many of them arent sure ... percent say that continuous oral contraceptive therapy to suppress ... survey results were presented by Kurt Barnhart MD, MSCE ...
... QUINCY, Mass., Oct. 3 The Stop & Shop Supermarket,Company, ... $75,000 to,Susan G. Komen for the Cure with the Pink ... Month," said Stop & Shop/Giant,Consumer Advisor Andrea Astrachan, "and by ... Giant, customers can support the fight against,breast cancer and help ...
... Inverness Medical,Innovations (Amex: IMA ) today announced ... both core laboratory and point of care,diagnostic testing products ... Inverness will pay an earn out up to a ... had,revenues of approximately $29.5m in 2006 and has been ...
... Workers in PA, MI, IL, FL, OH, MD, WI, WA Join Forces in, ... Equity ... Buyout, WASHINGTON, Oct. 3 ... union today,is launching a multi-state grassroots campaign calling on global buyout,giant the Carlyle ...
Cached Medicine News:Health News:Ralphs 'Pink Tag' Campaign to Raise $170,000 for Breast Cancer Awareness in October 2Health News:Safe to Stop the Flow?: Differing Attitudes Found Between Women and Doctors Concerning Menstrual Suppression 2Health News:Safe to Stop the Flow?: Differing Attitudes Found Between Women and Doctors Concerning Menstrual Suppression 3Health News:Differing attitudes found between women and doctors concerning menstrual suppression 2Health News:Stop & Shop and Giant Food Join General Mills in Pink for the Cure 2Health News:Inverness Medical Innovations Acquires Bio-Stat Healthcare Group 2Health News:SEIU Launches Multi-State Grassroots Campaign Calling on the Carlyle Group to Put Care Above Profits in Buyout of Nation's Largest Nursing Home Chain 2
(Date:12/17/2014)... STUTTGART , Alemania, December 17, 2014 ... del año anterior, con un alto nivel de gasto ... pasado año fiscal 2013/14 (finalizado el 30 de septiembre ... por ciento a 4.287 millones de euros (año anterior: ... de la moneda desfavorables. Las ganancias (EBIT) crecieron un ...
(Date:12/17/2014)... Dec. 17, 2014 With advancements in ... MRI market is seeing new growth, according to ... scans account for the majority of market volume, ... of images, which are creating opportunities for more sophisticated ... is growing at a rate of 4%, with ...
(Date:12/17/2014)...  IGI Laboratories, Inc. (NYSE MKT: IG; "IGI" or ... of $125 million aggregate principal amount of 3.75% Convertible ... offered and sold only to qualified institutional buyers pursuant ... as amended (the "Securities Act"). The Notes ... year, payable semiannually in arrears on June 15 and ...
Breaking Medicine Technology:ZEISS confirma su posición en un entorno difícil 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4
... March 5, 2012  RoundTable Healthcare Partners ("RoundTable"), an ... healthcare industry, announced today that Kent J. Davies ... RoundTable III Platform Development Corporation ("RPDC"), a Fund ... focus his attention on the identification and development ...
... -- Database101.com, a leading provider of email marketing, ... businesses and salespeople, will now offer its mailing lists and ... for marketers and salespeople. "Many marketers and small ... finding new ways to market successfully" said Vin Gupta, founder ...
Cached Medicine Technology:RoundTable Healthcare Partners Names Kent J. Davies CEO of Newly Formed Platform Development Corporation 2Database101.com Offers Hot Sales Leads & Email Lists, ONLINE, with NO Minimum Order! 2
... The TL-100 uses technology that takes ... by automatically detecting and reading them. It ... recording the results, mark lenses as you ... contact lenses. Easy to use, the TL-100 ...
... The Kowa RC-XV3 camera is ... The automatic exposure system, ... sensitivity, the 2.5~300ws watt indication ... handling are the basic features ...
FF 450plus fundus camera for 35mm photography. Upgradeable basic instrument for brilliant image quality....
The new TRC-NW6 non-mydriatic retinal camera is the ideal instrument for the growing market in telemedicine and diabetic screening....
Medicine Products: